Natalie S. Grover, MD, discusses the potential role of CD30-specific chimeric antigen receptor T cells in patients with relapsed/refractory Hodgkin Lymphoma.
Natalie S. Grover, MD
Advertisement
Articles by Natalie S. Grover, MD
Advertisement
Latest Updated Articles
CD30-Specific CAR T Cells in Patients With Relapsed/Refractory Hodgkin LymphomaPublished: March 6th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
